178 related articles for article (PubMed ID: 25851544)
1. Clinical-scale purification of pluripotent stem cell derivatives for cell-based therapies.
Rodrigues GM; Rodrigues CA; Fernandes TG; Diogo MM; Cabral JM
Biotechnol J; 2015 Aug; 10(8):1103-14. PubMed ID: 25851544
[TBL] [Abstract][Full Text] [Related]
2. A massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytes.
Hemmi N; Tohyama S; Nakajima K; Kanazawa H; Suzuki T; Hattori F; Seki T; Kishino Y; Hirano A; Okada M; Tabei R; Ohno R; Fujita C; Haruna T; Yuasa S; Sano M; Fujita J; Fukuda K
Stem Cells Transl Med; 2014 Dec; 3(12):1473-83. PubMed ID: 25355733
[TBL] [Abstract][Full Text] [Related]
3. Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
Ban K; Bae S; Yoon YS
Theranostics; 2017; 7(7):2067-2077. PubMed ID: 28638487
[TBL] [Abstract][Full Text] [Related]
4. The safety of human pluripotent stem cells in clinical treatment.
Simonson OE; Domogatskaya A; Volchkov P; Rodin S
Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
[TBL] [Abstract][Full Text] [Related]
5. Process engineering of human pluripotent stem cells for clinical application.
Serra M; Brito C; Correia C; Alves PM
Trends Biotechnol; 2012 Jun; 30(6):350-9. PubMed ID: 22541338
[TBL] [Abstract][Full Text] [Related]
6. Haematopoietic developmental potential of human pluripotent stem cell lines.
Tesařová L; Simara P; Stejskal S; Koutná I
Folia Biol (Praha); 2014; 60 Suppl 1():90-4. PubMed ID: 25369348
[TBL] [Abstract][Full Text] [Related]
7. Stable propagation of human embryonic and induced pluripotent stem cells on decellularized human substrates.
Abraham S; Sheridan SD; Miller B; Rao RR
Biotechnol Prog; 2010; 26(4):1126-34. PubMed ID: 20730767
[TBL] [Abstract][Full Text] [Related]
8. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
9. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes.
van den Heuvel NH; van Veen TA; Lim B; Jonsson MK
J Mol Cell Cardiol; 2014 Feb; 67():12-25. PubMed ID: 24370890
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells.
Hexum MK; Tian X; Kaufman DS
Methods Mol Biol; 2011; 767():433-47. PubMed ID: 21822894
[TBL] [Abstract][Full Text] [Related]
11. Integrated platform for production and purification of human pluripotent stem cell-derived neural precursors.
Rodrigues GM; Matos AF; Fernandes TG; Rodrigues CA; Peitz M; Haupt S; Diogo MM; Brüstle O; Cabral JM
Stem Cell Rev Rep; 2014 Apr; 10(2):151-61. PubMed ID: 24221956
[TBL] [Abstract][Full Text] [Related]
12. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards.
Martin RM; Fowler JL; Cromer MK; Lesch BJ; Ponce E; Uchida N; Nishimura T; Porteus MH; Loh KM
Nat Commun; 2020 Jun; 11(1):2713. PubMed ID: 32483127
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.
Kropp EM; Oleson BJ; Broniowska KA; Bhattacharya S; Chadwick AC; Diers AR; Hu Q; Sahoo D; Hogg N; Boheler KR; Corbett JA; Gundry RL
Stem Cells Transl Med; 2015 May; 4(5):483-93. PubMed ID: 25834119
[TBL] [Abstract][Full Text] [Related]
14. Isolation and cultivation of naive-like human pluripotent stem cells based on HERVH expression.
Wang J; Singh M; Sun C; Besser D; Prigione A; Ivics Z; Hurst LD; Izsvák Z
Nat Protoc; 2016 Feb; 11(2):327-46. PubMed ID: 26797457
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotyping of Live Human Pluripotent Stem Cells by Flow Cytometry.
Riordon DR; Boheler KR
Methods Mol Biol; 2018; 1722():127-149. PubMed ID: 29264803
[TBL] [Abstract][Full Text] [Related]
16. Engineering the human pluripotent stem cell microenvironment to direct cell fate.
Hazeltine LB; Selekman JA; Palecek SP
Biotechnol Adv; 2013 Nov; 31(7):1002-19. PubMed ID: 23510904
[TBL] [Abstract][Full Text] [Related]
17. Culturing human pluripotent stem cells for regenerative medicine.
Ozawa H; Matsumoto T; Nakagawa M
Expert Opin Biol Ther; 2023; 23(6):479-489. PubMed ID: 37345510
[TBL] [Abstract][Full Text] [Related]
18. The Tumorigenic Potential of Human Pluripotent Stem Cells.
Lezmi E; Benvenisty N
Stem Cells Transl Med; 2022 Aug; 11(8):791-796. PubMed ID: 35679163
[TBL] [Abstract][Full Text] [Related]
19. New medium used in the differentiation of human pluripotent stem cells to retinal cells is comparable to fetal human eye tissue.
Wang X; Xiong K; Lin C; Lv L; Chen J; Xu C; Wang S; Gu D; Zheng H; Yu H; Li Y; Xiao H; Zhou G
Biomaterials; 2015 Jun; 53():40-9. PubMed ID: 25890705
[TBL] [Abstract][Full Text] [Related]
20. The tumorigenic potential of pluripotent stem cells: What can we do to minimize it?
Peterson SE; Garitaonandia I; Loring JF
Bioessays; 2016 Jul; 38 Suppl 1():S86-95. PubMed ID: 27417126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
